The placebo treatments in neurosciences

  title={The placebo treatments in neurosciences},
  author={Nico Diederich and Christopher G Goetz},
  pages={677 - 684}
Placebo (PL) treatment is a method utilized as a control condition in clinical trials. A positive placebo response is seen in up to 50% of patients with Parkinson disease (PD), pain syndromes, and depression. The response is more pronounced with invasive procedures or advanced disease. Physiologic and biochemical changes have been studied in an effort to understand the mechanisms underlying placebo-related clinical improvement. In PD, objective clinical improvements in parkinsonism correlate… 

Figures and Tables from this paper

Neurobiology of placebo effect in Parkinson's disease: What we have learned and where we are going
Although the neural network underlying the placebo effect in PD has been largely confirmed and accepted, what remains to be established is how, when, and where the expectation of reward interacts with the primary motor system to induce clinical improvement in motor symptoms.
What influences placebo and nocebo responses in Parkinson's disease?
This review will focus on the effect of the placebo in patients with PD and will discuss the pathophysiology, observed characteristics of motor and nonmotor placebo responses, and the patient and study characteristics that modify the placebo response.
Placebo Effects in Traumatic Brain Injury.
Several of the primary psychological processes driving placebo effects as well as placebo neurobiology are examined, to explore whether something inherent in TBI makes it particularly responsive to placebos.
Placebo Effects in Neurological Diseases
This paper reviews recent articles about placebo effect, with an emphasis on its importance in several neurological conditions (Parkinson's disease, neuropathic pain, headache, multiple sclerosis, epilepsy), and intends to offer new insights on this major topic.
Harnessing the power of placebos in movement disorders: Insights from Parkinson's disease in clinical research and practice
This review describes the current knowledge about how to best make use of the placebo effect to improve clinical research and optimize clinical care and discusses how to minimize the ethical risks of using placebos.
Nocebo and lessebo effects.
  • Tiago A Mestre
  • Psychology, Medicine
    International review of neurobiology
  • 2020
Nocebo and lessebo effects
Psycho-Neuro-Endocrine-Immunological Basis of the Placebo Effect: Potential Applications beyond Pain Therapy
This review integrates current knowledge about the psycho-neuro-endocrine-immune basis of the placebo effect and its possible clinical applications and suggests a relationship between the placebo response and the opioid, cannabinoid, and monoaminergic systems.
Psychiatric Care in Parkinson’s Disease
  • R. Quelhas
  • Psychology, Medicine
    Journal of psychiatric practice
  • 2013
Therapeutic approaches to the treatment of PD and its associated psychiatric symptoms must be individualized and may involve a combination of antiparkinson drugs, psychopharmacological treatment, and/or psychotherapeutic interventions.


Understanding the Placebo Effect: Contributions from Neuroimaging
Evidence from positron emission tomography and functional magnetic resonance imaging studies suggests that expectations of symptom improvement are driven by frontal cortical areas, particularly the dorsolateral prefrontal, orbitofrontal, and anterior cingulate cortices.
The functional neuroanatomy of the placebo effect.
The common pattern of cortical glucose metabolism increases and limbic-paralimbic metabolism decreases in placebo and fluoxetine responders suggests that facilitation of these changes may be necessary for depression remission, regardless of treatment modality.
Changes in brain function of depressed subjects during treatment with placebo.
It is suggested that "effective" placebo treatment induces changes in brain function that are distinct from those associated with antidepressant medication, and cordance may be useful for differentiating between medication and placebo responders.
The Biochemical Bases for Reward
It is argued that placebo-induced dopamine release in limbic structures, particularly in the nucleus accumbens, could also be a major biochemical substrate for the placebo effect encountered in other medical disorders.
Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain
There is little evidence that decreasing the placebo response rate makes it more likely that superiority of active vs. placebo treatment will be demonstrated, and analyses of neuropathic pain clinical trial databases should be conducted to examine factors associated with trial outcomes.
Placebo effects on human μ-opioid activity during pain
The results suggest that endogenous opioid release in core affective brain regions is an integral part of the mechanism whereby expectancies regulate affective and nociceptive circuits.
The placebo response in Parkinson's disease. Parkinson Study Group.
Although there is clearly a placebo response in PD patients, a review suggests that the variation in placebo response does not correlate with demographic factors such as age, gender, religion, level of education, or duration of PD.
Expectation and Dopamine Release: Mechanism of the Placebo Effect in Parkinson's Disease
In vivo evidence is provided for substantial release of endogenous dopamine in the striatum of PD patients in response to placebo, indicating that the placebo effect in PD is powerful and is mediated through activation of the damaged nigrostriatal dopamine system.
Objective changes in motor function during placebo treatment in PD
All domains of parkinsonian disability were subject to placebo-associated improvement, with a trend toward more response in bradykinesia and rigidity than in tremor or gait/balance/midline function.